Healthcare professionals & adverse events of ChAdOx1 nCoV-19 coronavirus vaccine.
作者信息
Mungmunpuntipantip Rujittika, Wiwanitkit Viroj
机构信息
Consultant Unit, Private Academic Consultant, Bangkok, Thailand.
Department of Community Medicine, Dr. D. Y. Patil University, Pune 411 018, Maharashtra, India.
出版信息
Indian J Med Res. 2022 May-Jun;155(5&6):591. doi: 10.4103/ijmr.ijmr_373_22.
Abstract
摘要
相似文献
1
Healthcare professionals & adverse events of ChAdOx1 nCoV-19 coronavirus vaccine.医疗保健专业人员与ChAdOx1 nCoV-19冠状病毒疫苗的不良事件。
Indian J Med Res. 2022 May-Jun;155(5&6):591. doi: 10.4103/ijmr.ijmr_373_22.
2
Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey.报告接种 ChAdOx1 nCoV-19 冠状病毒疫苗（重组）的医护人员中的不良事件：一项横断面调查。
Indian J Med Res. 2022 Jan;155(1):123-128. doi: 10.4103/ijmr.ijmr_1221_21.
3
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.ChAdOx1 nCoV-19 和 BNT162b2 同源和异源加强免疫的安全性、反应原性和免疫原性：一项前瞻性队列研究。
Lancet Respir Med. 2021 Nov;9(11):1255-1265. doi: 10.1016/S2213-2600(21)00357-X. Epub 2021 Aug 13.
4
COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19.COVID-19 疫苗在免疫原性和炎症反应方面的类型依赖性差异：BNT162b2 和 ChAdOx1 nCoV-19。
Front Immunol. 2022 Sep 2;13:975363. doi: 10.3389/fimmu.2022.975363. eCollection 2022.
5
Balancing the reactogenicity of the ChAdOx1 nCov-19 vaccine against COVID-19 and the urgent need of a large immunization in healthcare workers.平衡ChAdOx1 nCov-19新冠疫苗的反应原性与医护人员大规模免疫的迫切需求。
Therapie. 2022 May-Jun;77(3):371-373. doi: 10.1016/j.therap.2021.07.004. Epub 2021 Jul 27.
6
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.《6-17 岁儿童中 ChAdOx1 nCoV-19（AZD1222）疫苗的安全性和免疫原性：COV006 的初步报告，一项 2 期、单盲、随机、对照试验》
Lancet. 2022 Jun 11;399(10342):2212-2225. doi: 10.1016/S0140-6736(22)00770-X.
7
Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.医护人员接种 ChAdOx1 nCoV-19 或 BNT162b2 mRNA COVID-19 疫苗第一针后出现的不良事件：单中心经验。
J Korean Med Sci. 2021 Apr 12;36(14):e107. doi: 10.3346/jkms.2021.36.e107.
8
Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal.接种 ChAdOx1 nCoV-19 和 BBIBP-CorV 疫苗后的不良反应：尼泊尔医护人员中的对比研究。
PLoS One. 2022 Aug 10;17(8):e0272729. doi: 10.1371/journal.pone.0272729. eCollection 2022.
9
Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.异源 ChAdOx1-nCoV-19/mRNA-1273 疫苗接种与同源 ChAdOx1-nCoV-19 或同源 mRNA-1273 疫苗接种的免疫反应和安全性比较。
J Formos Med Assoc. 2022 Apr;121(4):766-777. doi: 10.1016/j.jfma.2022.02.020. Epub 2022 Mar 16.
10
Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital.在朱拉隆功医院评估 ChAdox1 nCov-19（AZD1222）疫苗在实体瘤癌症患者中的免疫原性。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2104058. doi: 10.1080/21645515.2022.2104058. Epub 2022 Aug 17.
本文引用的文献
1
Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey.报告接种 ChAdOx1 nCoV-19 冠状病毒疫苗（重组）的医护人员中的不良事件：一项横断面调查。
Indian J Med Res. 2022 Jan;155(1):123-128. doi: 10.4103/ijmr.ijmr_1221_21.
2
Thrombosis After Adenovirus-Vectored COVID-19 Vaccination: A Concern on Underlying Illness.腺病毒载体新冠疫苗接种后的血栓形成：对潜在疾病的关注
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211060446. doi: 10.1177/10760296211060446.
3
Dengue After COVID-19 Vaccination: Possible and Might be Missed.新冠疫苗接种后的登革热：有可能发生且可能被漏诊。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211047229. doi: 10.1177/10760296211047229.
Zotero 插件